(je

0300

Docket No. 55672-A-PCT-US/JPW/AJM/MVM

In re application of: Gloria C. Li et al.

Serial No.: 09/750,410

December 28, 2000

FOT: 21 2002

Euses of dna-pk

November 19, 2002

U.S. Patent and Trademark Office

BOX: SEQUENCE P.O. Box 2327

Arlington, VA 22202

S I R:

Transmitted herewith is an amendment to the above-identified application.

Small entity status of this application under 37 C.P.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.

a verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.

X No additional fee is required.

The filing fee is calculated as follows:

	NUMBER		HIGHEST			NUMBER OF		1	RATE		FEE		
	AFTER AMEND- MENT		NUMBER PREVIOUSLY PAID FOR			EXTRA CLAIMS PRESENTED			SMALL Entity	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
Total Claims	26	-	*	26	=	***	0	x	9.00	18.00	=	0.00	j
Indepen- dent Claims	4	-	**	4	=	***	0	×	42.00	84.00	3	0.00	
Multiple Claims(s For Pirs) Presen		3 _	Yes		Х	No		140.00	280.00		0.00	
									TOTAL	ADDITI	ON	AL \$ 0.	.00

*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

**If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

***If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space. Applicants: Gloria C. Li et al.

U.S. Serial No: 09/750,410 Filed: December 28, 2000

Amendment Transmittal Letter

Page 2

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims as originally filed.

 Please	charge	Deposit	Account	No.	
in the	amount	of \$	<u> </u>		

____ A check in the amount of \$____ is enclosed.

- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3125 . Three copies of this sheet are enclosed.
 - Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.
 - X Any patent application processing fees under 37 C.F.R. §1.17.

I hereby certify that this correspondence is being deposited this date with the U.S. postal Service with sufficient postage as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office

Box: Sequence P.O. Box 2827

Arlington VA 22202

Alan J. Morrison Reg. No. 37,399 S/OZ

Respectfully submitted,

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

Cooper & Dunham LLP

New York, NY 10036

1185 Avenue of the Americas

John P. White

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/750,410

12/28/2000

Gloria C. Li

55672-A-PCT-US/ JPW/AJM/A

CONFIRMATION NO. 6916

FORMALITIES LETTER

OC000000008821165

Date Mailed: 09/19/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE